On-going work from our consortium on four topics:

Topic 1: Distinct molecular and cellular regulatory patterns in Fontan

Reimagining the fundamentals – “Coming back to the blackboard”

  • Hypothesis: a return to basic physiology and biochemistry is key to address the unique challenges in Fontan circulation.

  • Primary aim: to develop mechanistic approaches to comprehend  altered core physiological and biological processes in patients with a Fontan circulation.

  • Secondary aim: to reveal links between small molecule analytes on biochemistry basis, on transcriptomic and genomic basis that drive Fontan-related comorbidities and circulatory failure.

Topic 2: The Fontan Radar – Omics and biomarkers for insightful prognosis

Harnessing the power of advanced Biomarkers and Omics

  • Omics technologies are medical revolution. They are key to unraveling the complex origins of Fontan-related comorbidities.

  • Better biomarkers: we are also exploring the full potential of existing biomarkers, whether they are published in literature on Fontan circulation and general cardiology.

  • Aim: to develop an accurate prognosis: By strategically employing biomarkers, we aim to improve diagnostics, foresee long-term complications, and predict major adverse events with accuracy.

Topic 3: Understanding role of systemic and cardiac metabolism in Fontan

Metabolism: a major factor determining outcomes in Fontan?

  • Hypothesis: metabolic and regulatory processes, including oxidative stress, inflammation, and immunity, are determining Fontan outcomes.
  • Aim: We are integrating hemodynamic and metabolic evaluations to create a more complete picture of Fontan pathophysiology.

Topic 4: Pioneering development of Fontan metabolic therapies

Expanding treatment options to live a full life with half a heart.

  • Our consortium intends advancing clinical trials focused on metabolic interventions for selected subgroups of patients with a Fontan circulation.
  • Aim: To develop a comprehensive approach that extends from traditional therapies to lifestyle medicine for sustained quality of life.